Advocacy intelligence hub — real-time data for patient organizations
REBETOL: FDA approved
Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
REBETOL
Schering Corporation
REBETOL
(ribavirin)Orphan drugSchering Corporation
Nucleoside Analog Antiviral [EPC]
Mechanism of Action In cell cultures the inhibitory activity of ribavirin for respiratory syncytial virus (RSV) is selective. The mechanism of action ...
Browse all IgG4-related dacryoadenitis and sialadenitis news →
Ryuta Kamekura
Sapporo Medical University School of Medicine
Motohisa Yamamoto
IMSUT Hospital
Masatoshi Kanda
heumatology and Clinical Immunology
Ken Nagahata
heumatology and Clinical Immunology
Masafumi Moriyama
Kyushu University
Ken-Ichi Takano
Sapporo Medical University School of Medicine
View all IgG4-related dacryoadenitis and sialadenitis specialists →